TABLE 3-3 Amantadine Prophylaxis During Pandemic Influenza

Protective Efficacy
Pandemic/Subtype Influenza A Illness Seroconversion
1968 H3N2 59-100 28-52
1977 H1N1 31-71 18-39

NOTE: The values are the percentage ranges of reported efficacies in studies of oral amantadine.

SOURCE: The data are taken from Nafta et al. (1970), Oker-Blom et al. (1970), Smorodintsev et al. (1970), Monto et al. (1979), Pettersson et al. (1980) and Quarles et al. (1981).

From: 3, Toward Preparedness: Opportunities and Obstacles

Cover of The Threat of Pandemic Influenza
The Threat of Pandemic Influenza: Are We Ready? Workshop Summary.
Institute of Medicine (US) Forum on Microbial Threats; Knobler SL, Mack A, Mahmoud A, et al., editors.
Washington (DC): National Academies Press (US); 2005.
Copyright © 2005, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.